高危和极高危局限性前列腺癌的治疗选择

Treatment options for high-risk and extremely high-risk localized prostate cancer

摘要

关于高危和极高危局限性前列腺癌的治疗，泌尿外科、放疗科、肿瘤内科医生均有不同的见解。随着新的全身治疗药物的开发以及基因检测的应用，前列腺癌的治疗方法在不断更新。本文结合大量文献系统评估高危和极高危局限性前列腺癌患者选择不同治疗方法，如根治性前列腺切除术及淋巴结清扫术、放射治疗、全身治疗方案（以多西他赛为基础治疗、新型内分泌药物治疗、免疫及靶向治疗）等的远期生存及肿瘤控制疗效，以供临床参考。

Abstract

In the treatment of high-risk and extremely high-risk localized prostate cancer, urologists, radiation therapists and oncologists have different opinions. With the development of new systemic therapy drugs and the application of genetic testing, treatment methods are constantly evolving. This article reviews the latest research progress, including radical prostatectomy, lymph node dissection, radiotherapy, and systemic treatment regimens (docetaxel-based therapy, novel endocrinotherapy, immunotherapy, targeted therapy), to systematically evaluate the long-term survival and tumor control efficacy of different treatment methods, so as to provide clinical reference.

关键词

局限性前列腺癌 / 高危 / 极高危 / 放射治疗 / 根治性前列腺切除术 / 新型内分泌治疗 / 免疫治疗 / 靶向治疗 / 淋巴结清扫术 / 全身治疗

Key words

localized prostate cancer / high-risk / extremely high-risk / radiotherapy / radical prostatectomy / novel endocrinotherapy / immunotherapy / targeted therapy / lymph node dissection / systemic treatment

参考文献

[1] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）前列腺癌诊疗指南2023[M]. 北京： 人民卫生出版社， 2023.

[2] BASTIAN PJ, BOORJIAN SA, BOSSI A, et al. High-risk prostate cancer: from definition to contemporary management[J]. Eur Urol, 2012, 61(6): 1096-1106.

[3] 中国医促会泌尿健康促进分会， 中国研究型医院学会泌尿外科学专业委员会. 前列腺癌放射治疗安全共识[J]. 现代泌尿外科杂志， 2019， 24（5）： 336-346.

[4] TWARD JD, O'NEIL B, BOUCHER K, et al. Metastasis, mortality, and quality of life for men with nccn high and very high risk localized prostate cancer after surgical and/or combined modality radiotherapy[J]. Clin Genitourin Canc, 2020, 18(4): 274-283.

[5] HOLZBEIERLEIN JM. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer[J]. Cancer, 2011, 117(13): 2830-2832.

[6] KISHAN AU, SHAIKH T, WANG PC, et al. Clinical outcomes for patients with gleason score 9-10 prostate adenocarcinoma treated with radiotherapy or radical prostatectomy: a multi-institutional comparative analysis[J]. Eur Urol, 2017, 71(5): 766-773.

[7] WESTOVER K, CHEN MH, MOUL J, et al. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer[J]. BJU Int, 2012, 110(8): 1116-1121.

[8] EASTHAM JA, HELLER G, HALABI S, et al. Cancer and leukemia group B 90203 (alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer[J]. J Clin Oncol, 2020, 38(26): 3042-3050.

[9] 潘家骅， 刘家舟， 王勇， 等. 新辅助内分泌治疗联合化疗对极高危局部进展期前列腺癌疗效的多中心临床分析[J]. 中华泌尿外科杂志， 2021， 42（9）： 685-690.

[10] 华志雄， 毕建斌. 新辅助治疗的优势：机器人辅助腹腔镜下前列腺癌根治术治疗局部进展期前列腺癌[J]. 现代泌尿外科杂志， 2020， 25（4）： 319-321.

[11] FOSSATI N, WILLEMSE PM, VAN DEN BROECK T, et al. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review[J]. Eur Urol, 2017, 72(1): 84-109.

[12] LESTINGI J, GUGLIELMETTI GB, TRINH QD, et al. Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate-and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 trial[J]. Eur Urol, 2021, 79(5): 595-604.

[13] TOUIJER KA, SJOBERG DD, BENFANTE N, et al. Limited versus extended pelvic lymph node dissection for prostate cancer: a randomized clinical trial[J]. Eur Urol Oncol, 2021, 4(4): 532-539.

[14] OH J, TYLDESLEY S, PAI H, et al. An updated analysis of the survival endpoints of ASCENDE-RT[J]. Int J Radiat Oncol Biol Phys, 2023, 115(5): 1061-1070.

[15] MORRIS WJ, TYLDESLEY S, RODDA S, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high and intermediate-risk prostate cancer[J]. Int J Radiat Oncol Biol Phys, 2017, 98(2): 275-285.

[16] KOK D, GILL S, BRESSEL M, et al. Late toxicity and biochemical control in 554 prostate cancer patients treated with and without dose escalated image guided radiotherapy[J]. Radiother Oncol, 2013, 107(2): 140-146.

[17] DE CREVOISIER R, BAYAR MA, POMMIER P, et al. Daily versus weekly prostate cancer image guided radiation therapy: phase 3 multicenter randomized trial[J]. Int J Radiat Oncol Biol Phys, 2018, 102(5): 1420-1429.

[18] KERKMEIJER L, GROEN VH, POS FJ, et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase Ⅲ trial[J]. J Clin Oncol, 2021, 39(7): 787-796.

[19] TREE AC, SATCHWELL L, ALEXANDER E, et al. Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: 5-year efficacy and toxicity in the DELINEATE trial[J]. Int J Radiat Oncol Biol Phys, 2023, 115(2): 305-316.

[20] KISHAN AU, DANG A, KATZ AJ, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer[J]. JAMA Netw Open, 2019, 2(2): e188006.

[21] JACKSON WC, SILVA J, HARTMAN HE, et al. Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6000 patients treated on prospective studies[J]. Int J Radiat Oncol Biol Phys, 2019, 104(4): 778-789.

[22] ANDERS W, ADALSTEINN G, LARS B, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial[J]. Lancet, 2019, 394(10196): 385-395.

[23] MURTHY V, MAITRE P, KANNAN S, et al. Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase Ⅲ randomized controlled trial[J]. J Clin Oncol, 2021, 39(11): 1234-1242.

[24] HACKMAN G, TAARI K, TAMMELA TL, et al. Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension[J]. Eur Urol, 2019, 76(5): 586-595.

[25] PARKER C, SYDES MR, CATTON C, et al. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new medical research council/National Cancer Institute of Canada phase Ⅲ trial of adjuvant treatment after radical prostatectomy[J]. BJU Int, 2007, 99(6): 1376-1379.

[26] PEARSE M, FRASER-BROWNE C, DAVIS ID, et al. A phase Ⅲ trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the radiotherapy-adjuvant versus early salvage (RAVES) trial[J]. BJU Int, 2014, 113(Suppl 2): 7-12.

[27] UNICANCER. Triptorelin and radiation therapy in treating patients who have undergone surgery for intermediate-risk stage Ⅲ or stage Ⅳ prostate cancer 2008 [ Clinical Trials.gov trial. NCT00667069]. https://clinicaltrials.gov/ct2/show/NCT00667069?term=NCT00667069&rank=1.

[28] VALE CL, FISHER D, KNEEBONE A, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregated data[J]. Lancet, 2020, 396(10260): 1422-1431.

[29] ZELEFSKY MJ, FUKS Z, HUNT M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer[J]. J Urol, 2001, 166(3): 876-881.

[30] FIZAZI K, CARMEL A, JOLY F, et al. Updated results of GETUG-12, a phase Ⅲ trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up[J]. Ann Oncol, 2018, 29(suppl_8): Ⅷ271-Ⅷ302.

[31] JAMES ND, SYDES MR, CLARKE NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial[J]. Lancet, 2016, 387(10024): 1163-1177.

[32] KOONTZ BF, HOFFMAN KE, HALABI S, et al. Combination of radiation therapy and short-term androgen blockade with abiraterone acetate plus prednisone for men with high-and intermediate-risk localized prostate cancer[J]. Int J Radiat Oncol Biol Phys, 2021, 109(5): 1271-1278.

[33] SANDLER HM, SANDLER HM, MCKENZIE MR, et al. ATLAS: a randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy[J]. J Clin Oncol, 2016, 34(15_suppl): S5087.

[34] WILLIAMS S, DAVIS ID, SWEENEY C, et al. Randomised phase Ⅲ trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised, high risk, or node-positive prostate cancer: ENZARAD (ANZUP 1303)[J]. J Clin Oncol, 2017, 35(15_suppl): S5096.

[35] ANTONARAKIS ES, PIULATS JM, GROSS-GOUPIL M, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase Ⅱ KEYNOTE-199 study[J]. J Clin Oncol, 2020, 38(5): 395-405.

[36] ANTONARAKIS ES, PARK SH, GOH JC, et al. Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase Ⅲ KEYLYNK-010 trial[J]. J Clin Oncol, 2023, 41(22): 3839-3850.

[37] TAGAWA ST, ZHANG J, MONK P, et al. BXCL701: first-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small-cell neuroendocrine carcinoma (SCNC) phenotype-phase 2A interim results[J]. J Clin Oncol, 2022, 40(6_suppl): 126.

[38] DE BONO J, MATEO J, FIZAZI K, et al. Olaparib for metastatic castration-resistant prostate cancer[J]. N Engl J Med, 2020, 382(22): 2091-2102.

[39] GOMEZ-ITURRIAGA A, BÜCHSER D, LOPEZ-CAMPOS F, et al. Enhancing androgen deprivation therapy (ADT) integration in prostate cancer: insights for stereotactic body radiotherapy (SBRT) and brachytherapy modalities[J]. Clin Transl Radiat Oncol, 2024, 45: 100733.

[40] ZHUANG J, ZHANG S, QIU X, et al. Neoadjuvant pamiparib plus abiraterone and ADT for high-risk/very high-risk localized prostate cancer: results of a prospective study[J]. J Clin Oncol, 2024, 42(4_suppl): 327.